Remgro Limited (FRA:RE7)
Germany · Delayed Price · Currency is EUR | Market Cap | 5.97B +26.3% |
| Revenue (ttm) | 2.72B +0.9% |
| Net Income | 76.76M -56.5% |
| EPS | 0.14 -57.1% |
| Shares Out | n/a |
| PE Ratio | 80.51 |
| Forward PE | 9.80 |
| Dividend | 0.62 (5.67%) |
| Ex-Dividend Date | Oct 21, 2026 |
| Volume | 270 |
| Open | 10.60 |
| Previous Close | 10.60 |
| Day's Range | 10.60 - 10.90 |
| 52-Week Range | 8.30 - 11.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 24, 2027 |
About Remgro
Remgro Limited is a principal investment firm. The firm prefers to invest in healthcare, financial services, consumer products, infrastructure, industrial, food, liquor and home care, banking, insurance, industrial, information technology infrastructure services, media, and sport. It considers investments in Africa, UAE, UK, Switzerland, South Africa, and other international countries though investee companies. The firm typically invests in companies with significant influence and board representation. It mainly focuses on the provision of supp... [Read more]
Financial Performance
In fiscal year 2026, Remgro's revenue was 51.01 billion, an increase of 0.89% compared to the previous year's 50.56 billion. Earnings were 1.44 billion, a decrease of -56.46%.
Financial numbers in ZAR Financial StatementsNews
Remgro Earnings Call Transcript: H2 2026
Headline earnings surged 42.3% to ZAR 11.1 billion, driven by strong operational performance and portfolio optimization, enabling a 73% dividend increase and a special payout. Major segments like Mediclinic, Heineken Beverages, and CIVH delivered robust growth, while RCL Foods faced headwinds.
Remgro Annual report: H2 2026
Remgro has published its H2 2026 annual report on September 21, 2026.
Remgro Slides: H2 2026
Remgro has posted slides in relation to its H2 2026 quarterly earnings report, which was published on September 21, 2026.
Remgro Earnings Call Transcript: H1 2026
Headline earnings surged 38.8% year-over-year, driven by strong performances from Mediclinic, CIVH, Rainbow, and Heineken Beverages, supporting an 80% interim dividend increase. Portfolio simplification and robust cash generation position the group well amid ongoing macroeconomic and geopolitical volatility.
Remgro Quarterly report: H1 2026
Remgro has published its H1 2026 quarterly earnings report on March 25, 2026.
Remgro Slides: H1 2026
Remgro has posted slides in relation to its H1 2026 quarterly earnings report, which was published on March 25, 2026.
Remgro Earnings release: H1 2026
Remgro released its H1 2026 earnings on March 13, 2026, summarizing the period's financial results.
Remgro Earnings Call Transcript: H2 2025
Headline earnings surged 38.6% year-over-year, driven by strong contributions from key portfolio companies and improved operational performance. The group declared a 30.3% higher total dividend and a special dividend, while advancing portfolio simplification and degearing.
Remgro Annual report: H2 2025
Remgro has published its H2 2025 annual report on September 23, 2025.
Remgro Annual report: H2 2025
Remgro has published its H2 2025 annual report on September 23, 2025.
Remgro Slides: H2 2025
Remgro has posted slides in relation to its H2 2025 quarterly earnings report, which was published on September 23, 2025.
Remgro Transcript: Investor Update
Regulatory approval is progressing, with enhanced commitments leading to Competition Commission support and an Appeals Court decision expected by September. The transaction values Maziv at ZAR 36 billion, includes significant CapEx and BEE commitments, and is expected to improve Remgro's profitability.
Remgro Slides: Investor Update
Remgro has posted slides in relation to its latest quarterly earnings report, which was published on July 21, 2025.
Remgro Transcript: CMD 2025
The event highlighted a strategic shift to private assets, active portfolio management, and disciplined capital allocation, with a focus on organic growth, partnerships, and operational efficiency. Key updates included Mediclinic’s turnaround and CIVH’s fibre expansion, while challenges remain in underperforming assets and regulatory delays.
Remgro Slides: FY 2025
Remgro has posted slides in relation to its FY 2025 quarterly earnings report, which was published on April 14, 2025.
Remgro upgraded to Buy from Hold at Investec
Investec analyst Dino Constantinou upgraded Remgro (RMGOF) to Buy from Hold with an ZAR 186 price target
Remgro Earnings Call Transcript: H1 2025
Headline earnings rose 38.7% to ZAR 3.7 billion, driven by strong operational gains in key portfolio companies and a return to profitability at Heineken Beverages. The balance sheet was de-geared, enabling a 20% dividend increase and flexibility for new investments.
Remgro Quarterly report: H1 2025
Remgro has published its H1 2025 quarterly earnings report on March 25, 2025.
Remgro Slides: H1 2025
Remgro has posted slides in relation to its H1 2025 quarterly earnings report, which was published on March 25, 2025.
Remgro Transcript: AGM 2024
The AGM covered board elections, executive incentives, and strategic portfolio moves, with shareholders actively engaging on governance, diversity, and geopolitical risks. All resolutions were approved, and management highlighted improvements in key investments and a focus on sustainable value creation.
Remgro’s investment in Vumatel and DFA hitting a bumpy patch
Remgro’s investment in South Africa’s telecommunications sector through Community Investment Ventures Holdings (CIVH) is hitting a bumpy patch.
Remgro upgraded to Hold from Sell at Investec
Investec upgraded Remgro to Hold from Sell with a ZAR 150 price target.
Vumatel-owner now a R25.4 billion fibre giant – despite losing money
Remgro's valuation of CIVH has increased to well over R25 billion – despite the Vumatel-owner reporting a significant financial loss.
Heineken leaves a bad taste
Remgro's results for the past financial year reveal Heineken Beverages remains under significant pressure.
Remgro Earnings Call Transcript: H2 2024
Headline earnings declined 20% year-over-year due to non-recurring items and a tough macro environment, but the second half saw improved performance and a 10% increase in the annual dividend. Key investments like Mediclinic, Heineken, and CIVH faced challenges, while OUTsurance and RCL Foods delivered strong results.